2022
The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study
Morford K, Tetrault J, Zhou B, Li F, Gleeson B, Edelman E, Stein M, Barry D, Madden L. The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study. Drug And Alcohol Dependence 2022, 241: 109707. PMID: 36423462, PMCID: PMC9777057, DOI: 10.1016/j.drugalcdep.2022.109707.Peer-Reviewed Original ResearchConceptsBenzodiazepine exposureRetrospective cohort studyKaplan-Meier analysisTreatment retentionCohort studyCox regressionTreatment durationMedian treatment durationMultivariable Cox regressionCohort of patientsOpioid treatment programsOpioid use disorderLog-rank testSame-day accessDrug Administration recommendationsTreatment discontinuationUrine toxicologyMeier analysisMethadone programsUse disordersPatientsAdministration recommendationsTreatment entryTreatment programTreatment barriers
2020
Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention
Severe B, Tetrault JM, Madden L, Heimer R. Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention. Drug And Alcohol Dependence 2020, 213: 108116. PMID: 32599493, DOI: 10.1016/j.drugalcdep.2020.108116.Peer-Reviewed Original ResearchOpioid treatment programsOpioid use disorderOpioid agonist treatmentHCV treatmentOUD treatmentTreatment retentionHepatitis C virus infection treatmentControl groupSurvival analysisHepatitis C virus infectionTreatment programHCV care continuumC virus infectionChronic HCV infectionOutcomes of interestHCV infectionAgonist treatmentPatient retentionCare continuumVirus infectionTreatment groupsUse disordersPatientsBaseline covariatesInfection treatment
2006
A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, O'Connor PG, Schottenfeld RS, Fiellin DA. A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care. Clinical Infectious Diseases 2006, 43: s184-s190. PMID: 17109305, DOI: 10.1086/508182.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, SublingualAdultAntiretroviral Therapy, Highly ActiveBuprenorphineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPilot ProjectsProbabilityReference ValuesRisk FactorsTreatment OutcomeConceptsHIV clinical careHIV-1 RNA copies/mLBuprenorphine/naloxone treatmentRNA copies/mLCopies/mLOpioid dependenceClinical careOpioid useNaloxone treatmentPhysician managementTreatment retentionHIV type 1 RNA levelsHIV-1 RNA levelsDose of buprenorphinePartial opioid agonistRNA levelsCD4 lymphocyte countBuprenorphine/naloxoneOpioid-dependent patientsUrine toxicology testsWeeks of treatmentHuman immunodeficiency virusUrine test resultsBetter treatment retentionUntreated opioid dependence